Onkologie. 2019:13(5):209-213 | DOI: 10.36290/xon.2019.040

Immunotherapy in urothelial cancer

Alexandr Poprach, Radek Lakomý, Jiří Navrátil

Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MU, Brno

The treatment of patients with the locally advanced or metastatic urothelial cancer is enriched by the immunotherapy. The immunotherapy is superior in pacients unfit for cisplatine. After the failure platinum based chemotherapy, the immunotherapy provided very similar results in overall survival and overall response rate like the chemotherapy, but we have to emphasize the better quality of life in the patients treated by immunotherapy. And to another point, in patients with responses on the immunotherapy, these responses are often prolonging. The probabilities of being alive are two or three times longer comparing with chemotherapy too. Up to date, the immunotherapy is also efficient in neoadjuvant settings and in non-muscle invasive bladder cancer. It is pretty clear that immunotherapy will have a crucial role in the therapy of patients with urothelial cancer.

Keywords: immunotherapy, checkpoint inhibitors, overall survival

Published: October 20, 2019  Show citation